Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DTS-201: Phase I data

In a Phase I trial in 25 patients, the maximum tolerated

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE